Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00018)
Name |
Osteosarcoma
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: 2B51
|
Full List of Target(s) of This Ferroptosis-centered Disease
Cystine/glutamate transporter (SLC7A11)
In total 6 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Bavachin | Investigative | |||
Responsed Regulator | Signal transducer and activator of transcription 3 (STAT3) | Suppressor | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | ||
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Bavachin | Investigative | |||
Responsed Regulator | Cellular tumor antigen p53 (TP53) | Driver | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | ||
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [9] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Tirapazamine | Phase 3 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
In Vitro Model | 143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
MNNG/HOS Cl #5 cells | Osteosarcoma | Homo sapiens | CVCL_0439 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
Response regulation | SLC7A11 overexpression could restored the proliferation and migration abilities inhibited by Tirazamine. Thus, TPZ could inhibit the proliferation and migration of osteosarcoma cells, and induce ferroptosis in part through inhibiting SLC7A11. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [10] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | Lysine-specific demethylase 4A (KDM4A) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell metastasis | |||||
In Vitro Model | 143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | ||
In Vivo Model |
For the xenograft mouse model, 1 x 106 OS 143B cells in 100 uL PBS were subcutaneously injected with 1 x 106 OS cells. For the OS lung metastasis model and in vivo imaging, 1 x 106 143B cells in 10 uL PBS were injected orthotopically into the medullary cavity of the tibia of mice. For bioluminescent imaging, we used 143B cells stably expressing luciferase, and the luciferase substrate D-Luciferin (Selleck, China) was retro-orbitally injected before imaging on days 7 and 21.
Click to Show/Hide
|
||||
Response regulation | KDM4A regulates SLC7A11 transcription and osteosarcoma cell ferroptosis by controlling H3K9me3 demethylation in the promoter region of SLC7A11. The findings suggestes that KDM4A activity may be a potential therapeutic target for future OS treatment. | ||||
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target | [11] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | hsa-miR-206 (miRNA) | Driver | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | SJSA-1 cells | Osteosarcoma | Homo sapiens | CVCL_1697 | |
Response regulation | LncRNA SNHG14 targeted and down-regulated the expression of miR-206, further affecting the common ferroptosis inhibitor SLC7A11, and preventing NR-SJSA1 cells from undergoing ferroptosis. In conclusion, our findings highlight the involvement of lncRNA SNHG14 in ferroptosis and chemotherapy resistance of nutlin3a-resistant NR-SJSA1 cells, thus shedding new insight on how to overcome drug resistance in osteosarcoma cells and improve treatment efficacy. | ||||
Experiment 6 Reporting the Ferroptosis-centered Disease Response by This Target | [11] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | SNHG14 (IncRNA) | Suppressor | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | SJSA-1 cells | Osteosarcoma | Homo sapiens | CVCL_1697 | |
Response regulation | LncRNA SNHG14 targeted and down-regulated the expression of miR-206, further affecting the common ferroptosis inhibitor SLC7A11, and preventing NR-SJSA1 cells from undergoing ferroptosis. In conclusion, our findings highlight the involvement of lncRNA SNHG14 in ferroptosis and chemotherapy resistance of nutlin3a-resistant NR-SJSA1 cells, thus shedding new insight on how to overcome drug resistance in osteosarcoma cells and improve treatment efficacy. | ||||
Unspecific Target
In total 7 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Zoledronic acid | Investigative | |||
Responsed Regulator | NADPH--cytochrome P450 reductase (POR) | Driver | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | ||
In Vivo Model |
All animal experimentation was approved by the Ethics Committee of The Eighth Affiliated Hospital of Sun Yat-sen University. Each group consisted of five female BALB/c nude 4-week-old mice, and the studies were run twice. 143B cells were treated with ZOL or DMEM containing 10% FBS for 2 days. Two sets of BALB/c nude mice were used in the study (ZOL group and NC group). The ZOL group and NC group were subcutaneously injected with ZOL-treated 143B cells or normal 143B cells, respectively, to form xenograft tumors. After 2 weeks, we subcutaneously injected 100 ul ZOL (100 ug/kg) into the experimental group and 100 ul saline into the NC group twice a week. Then, after 4 weeks, mice from both groups were humanely killed, the tumor diameter was measured, and the tumor tissue was stained with HE.
Click to Show/Hide
|
||||
Response regulation | Zoledronic acid (ZOL) induces ferroptosis by upregulating POR expression to increase ROS levels and upregulate lipid peroxidation levels in osteosarcoma cells. POR may be used as a therapeutic target to inhibit osteosarcoma. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [12] | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Phenethyl isothiocyanate | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Autophagy | hsa04140 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell apoptosis | |||||
Cell autophagy | |||||
In Vitro Model | K7M2-WT cells | Osteosarcoma | Mus musculus | CVCL_V455 | |
In Vivo Model |
Male BALB/c mice, aged 4 weeks (14-16 g), were purchased from SPF (Beijing) Biotechnology Co., Ltd. K7M2 osteosarcoma cells were harvested and suspended in PBS at 4 . Mice were anesthetized with isoflurane. The left hindlimbs were shaved and cleaned with 75% ethanol. The knees of the mice were flexed beyond 90 and the cortex of the proximal tibial crest was penetrated using a 25 gauge needle by a rotating action. Once the tibial bone cortex was penetrated, the needles were further inserted 2 mm along the diaphysis, followed by injection of 10 uL of K7M2 osteosarcoma cells (5 x 105 cells) into the tibia.
Click to Show/Hide
|
||||
Response regulation | Phenethyl isothiocyanate (PEITC) induces ferroptosis, autophagy, and apoptosis in K7M2 osteosarcoma cells by activating the ROS-related MAPK signaling pathway. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [13] | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Phenethyl isothiocyanate | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Apoptosis | hsa04210 | ||||
Autophagy | hsa04140 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
Cell autophagy | |||||
Cell proliferation | |||||
In Vitro Model | MNNG/HOS Cl #5 cells | Osteosarcoma | Homo sapiens | CVCL_0439 | |
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | ||
Response regulation | Phenethyl isothiocyanate (PEITC) reduced cell viability, inhibited proliferation, caused #REF!/M cell cycle arrest, altered iron metabolism, induced GSH depletion, generated ROS, activated MAPK signaling pathway, and triggered multiple cell death modalities, mainly ferroptosis, apoptosis, and autophagy, in human osteosarcoma cells. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [14] | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | Fanconi anemia group D2 protein (FANCD2) | Suppressor | |||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
hFOB 1.19 cells | Normal | Homo sapiens | CVCL_3708 | ||
In Vivo Model |
Thirty BALB/c nude mice (20~22 g, five weeks) were SiPeiFu Biotechnology Co., Ltd. (Beijing, China). Animal experiment was conducted in accordance with China Animal Welfare Legislation and was approved by the Ethics Committee of our hospital. U2OS cells (1 x 106 cells) were subcutaneously injected into mice to establish osteosarcoma mice models. The mice were randomized into Lv-si-NC and Lv-si-FANCD2 groups (n = 6). After modeling, lentivirus-packaged si-FANCD2-1 and si-NC were locally injected into tumor tissues of mice in the Lv-si-FANCD2 and Lv-si-NC groups, respectively. They were euthanized by intraperitoneal injection of sodium pentobarbital (50 mg/kg) after 28 days, the tumor tissues were collected and weight was measured.
Click to Show/Hide
|
||||
Response regulation | FANCD2 silencing could suppress osteosarcoma cell viability, migration, invasion, and tumor growth, and induced ferroptosis by regulating the JAK2/STAT3 axis. | ||||
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target | [15] | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | Suppressor of cytokine signaling 1 (SOCS1) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | |
IMR-90 cells | Normal | Homo sapiens | CVCL_0347 | ||
Response regulation | SOCS1 impacts the pattern of secreted products in cells with active p53 and is required for the expression of a selective set of p53 target genes including those involved in ferroptosis. SOCS1 can use several mechanisms to activate p53, including promotion of serine-15 phosphorylation by ATM/ATR kinases and inhibition of the p53 repressor KAP1 in osteosarcoma cell lines. | ||||
Experiment 6 Reporting the Ferroptosis-centered Disease Response by This Target | [16] | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | Hypoxia-inducible lipid droplet-associated protein (HILPDA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
In Vitro Model | U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | |
MNNG/HOS Cl #5 cells | Osteosarcoma | Homo sapiens | CVCL_0439 | ||
Response regulation | Both HILPDA and MUC1 were reported ferroptosis-related regulators. Interfering HILPDA and MUC1 expression would inhibit tumor cell proliferation and migration, and MUC1 might improve the ferroptosis resistance of osteosarcoma (OS) cells. | ||||
Experiment 7 Reporting the Ferroptosis-centered Disease Response by This Target | [15] | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | Cellular tumor antigen p53 (TP53) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | |
IMR-90 cells | Normal | Homo sapiens | CVCL_0347 | ||
Response regulation | SOCS1 impacts the pattern of secreted products in cells with active p53 and is required for the expression of a selective set of p53 target genes including those involved in ferroptosis. SOCS1 can use several mechanisms to activate p53, including promotion of serine-15 phosphorylation by ATM/ATR kinases and inhibition of the p53 repressor KAP1 in osteosarcoma cell lines. | ||||
Transferrin receptor protein 1 (TFRC)
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
Target for Ferroptosis | Marker/Suppressor/Driver | |||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | |||
Responsed Drug | Bavachin | Investigative | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | |||
Prostaglandin G/H synthase 2 (PTGS2)
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | |||
Target for Ferroptosis | Marker | |||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | |||
Responsed Drug | Zoledronic acid | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | HEK-293T cells | Normal | Homo sapiens | CVCL_0063 |
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | |
MNNG/HOS Cl #5 cells | Osteosarcoma | Homo sapiens | CVCL_0439 | |
Response regulation | Zoledronic acid treatment decreased cell viability and promoted the increase in lipid peroxide content and PTGS2 expression. Our results indicate that zoledronic acid induces ferroptosis by decreasing ubiquinone content and promoting HMOX1 expression in osteosarcoma cells. | |||
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 4 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [4] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Baicalin | Terminated | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | ||
hBMMSCs (Human bone marrow mesenchymal stem cells) | |||||
In Vivo Model |
A total of 24 BALB/c-nude mice (4-5 weeks old) were purchased and MG63 cells were injected into the right tibial bone marrow cavity of mice in a volume of 1 x 106/100 ul. When the tumor volume was visible, all animals were randomly divided into four groups (n = 6): the control (10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline) group, the baicalin (200 mg/kg/day) group, the Fer-1 (0.8 mg/kg/day) group and Fer-1 + baicalin group. The baicalin and Fer-1 were intraperitoneally administered every day for two consecutive weeks and tumor sizes were measured every two days.
Click to Show/Hide
|
||||
Response regulation | By promoting the Fe accumulation, ROS formation, MDA production and suppressing the ratio of GSH/GSSG, baicalin was found to trigger ferroptosis in Osteosarcoma and ferroptosis inhibitor ferrostatin-1 (Fer-1) successfully reversed these suppressive effects, indicating that ferroptosis participated in the baicalin mediated anti-OS activity. Mechanistically, baicalin physically interacted with Nrf2, a critical regulator of ferroptosis, and influenced its stability via inducing ubiquitin degradation, which suppressed the Nrf2 downstream targets GPX4 and xCT expression, and led to stimulating ferroptosis. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | Zinc finger E-box-binding homeobox 1 (ZEB1) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model | 143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
SW1353 cells | Bone chondrosarcoma | Homo sapiens | CVCL_0543 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
HOB (Human normal osteoblastic cells) | |||||
In Vivo Model |
The OS model of nude mice was constructed using the CDTX model. After transfection, the h143B cells were prepared into a single-cell suspension and subcutaneously injected into the left proximal tibia of 36 (3 mice per group) 4-weeks-old nude mice (1 x 107 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | MiR-144-3p can induce the occurrence of ferroptosis by negatively regulating the expression of ZEB1, thereby inhibiting the proliferation, migration, and invasion of osteosarcoma (OS) cells. The overexpression of ZEB1 caused the lower expression level of ACSL4 and higher expression level of xCT and GPX4. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | hsa-miR-144-3p (miRNA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model | 143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
SW1353 cells | Bone chondrosarcoma | Homo sapiens | CVCL_0543 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
HOB (Human normal osteoblastic cells) | |||||
In Vivo Model |
The OS model of nude mice was constructed using the CDTX model. After transfection, the h143B cells were prepared into a single-cell suspension and subcutaneously injected into the left proximal tibia of 36 (3 mice per group) 4-weeks-old nude mice (1 x 107 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | MiR-144-3p can induce the occurrence of ferroptosis by negatively regulating the expression of ZEB1, thereby inhibiting the proliferation, migration, and invasion of osteosarcoma (OS) cells. The overexpression of ZEB1 caused the lower expression level of ACSL4 and higher expression level of xCT and GPX4. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | hsa-miR-1287-5p (miRNA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | hFOB 1.19 cells | Normal | Homo sapiens | CVCL_3708 | |
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
Response regulation | MiR-1287-5p directly bound to the 3'-untranslated region of glutathione peroxidase 4 (GPX4) to inhibit its protein level and activity, and that GPX4 overexpression completely abolished the miR-1287-5p mimic-mediated ferroptotic induction and tumor suppression. The findings prove that miR-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4. | ||||
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [4] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Baicalin | Terminated | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | ||
hBMMSCs (Human bone marrow mesenchymal stem cells) | |||||
In Vivo Model |
A total of 24 BALB/c-nude mice (4-5 weeks old) were purchased and MG63 cells were injected into the right tibial bone marrow cavity of mice in a volume of 1 x 106/100 ul. When the tumor volume was visible, all animals were randomly divided into four groups (n = 6): the control (10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline) group, the baicalin (200 mg/kg/day) group, the Fer-1 (0.8 mg/kg/day) group and Fer-1 + baicalin group. The baicalin and Fer-1 were intraperitoneally administered every day for two consecutive weeks and tumor sizes were measured every two days.
Click to Show/Hide
|
||||
Response regulation | By promoting the Fe accumulation, ROS formation, MDA production and suppressing the ratio of GSH/GSSG, baicalin was found to trigger ferroptosis in Osteosarcoma and ferroptosis inhibitor ferrostatin-1 (Fer-1) successfully reversed these suppressive effects, indicating that ferroptosis participated in the baicalin mediated anti-OS activity. Mechanistically, baicalin physically interacted with Nrf2, a critical regulator of ferroptosis, and influenced its stability via inducing ubiquitin degradation, which suppressed the Nrf2 downstream targets GPX4 and xCT expression, and led to stimulating ferroptosis. | ||||
Natural resistance-associated macrophage protein 2 (SLC11A2)
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | |||
Responsed Drug | Bavachin | Investigative | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 (SLC11A2) expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | |||
Long-chain-fatty-acid--CoA ligase 4 (ACSL4)
In total 2 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Driver | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | Zinc finger E-box-binding homeobox 1 (ZEB1) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model | 143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
SW1353 cells | Bone chondrosarcoma | Homo sapiens | CVCL_0543 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
HOB (Human normal osteoblastic cells) | |||||
In Vivo Model |
The OS model of nude mice was constructed using the CDTX model. After transfection, the h143B cells were prepared into a single-cell suspension and subcutaneously injected into the left proximal tibia of 36 (3 mice per group) 4-weeks-old nude mice (1 x 107 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | MiR-144-3p can induce the occurrence of ferroptosis by negatively regulating the expression of ZEB1, thereby inhibiting the proliferation, migration, and invasion of osteosarcoma (OS) cells. The overexpression of ZEB1 caused the lower expression level of ACSL4 and higher expression level of xCT and GPX4. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Driver | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Regulator | hsa-miR-144-3p (miRNA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model | 143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
SW1353 cells | Bone chondrosarcoma | Homo sapiens | CVCL_0543 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
HOB (Human normal osteoblastic cells) | |||||
In Vivo Model |
The OS model of nude mice was constructed using the CDTX model. After transfection, the h143B cells were prepared into a single-cell suspension and subcutaneously injected into the left proximal tibia of 36 (3 mice per group) 4-weeks-old nude mice (1 x 107 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | MiR-144-3p can induce the occurrence of ferroptosis by negatively regulating the expression of ZEB1, thereby inhibiting the proliferation, migration, and invasion of osteosarcoma (OS) cells. The overexpression of ZEB1 caused the lower expression level of ACSL4 and higher expression level of xCT and GPX4. | ||||
Heme oxygenase 1 (HMOX1)
In total 2 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [7] | |||
Target for Ferroptosis | Driver/Suppressor | |||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | |||
Responsed Drug | 3,5-bis((E)-2-fluorobenzylidene)piperidin-4-one hydrochloride | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model | U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 |
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | |
Response regulation | 3,5-bis((E)-2-fluorobenzylidene)piperidin-4-one hydrochloride (EF24) upregulated HMOX1 to suppress GPX4 expression to induce ferroptosis by increasing MDA level, ROS level and intracellular ferric ion level. Thus, EF24 might serve as a potential agent for the treatment of HMOX1-positive osteosarcoma patients. | |||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | |||
Responsed Drug | Zoledronic acid | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | HEK-293T cells | Normal | Homo sapiens | CVCL_0063 |
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | |
MNNG/HOS Cl #5 cells | Osteosarcoma | Homo sapiens | CVCL_0439 | |
Response regulation | Zoledronic acid treatment decreased cell viability and promoted the increase in lipid peroxide content and PTGS2 expression. Our results indicate that zoledronic acid induces ferroptosis by decreasing ubiquinone content and promoting HMOX1 expression in osteosarcoma cells. | |||
Ferritin light chain (FTL)
In total 2 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Bavachin | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | ||
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [8] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Ursolic Acid | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell apoptosis | |||||
Cell autophagy | |||||
In Vitro Model | HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | ||
In Vivo Model |
NU/NU mice (the Fourth Military Medical University, Shaanxi, China) were injected with 143B cells (100 uL, 5 x 107 cells/mL, i.h.). Seven days after the injection, the mice were divided into 6 different groups (n= 3) and intraperitoneally injected with different drugs twice a week. Then, on day 28, the mice were sacrificed, and the tumours in the different groups were weighed. Body weight and tumour size were measured every 3 days from day 7 to day 28. The tumour tissue was fixed with 4% paraformaldehyde, embedded in paraffin, and cut into 4 um thick sections for haematoxylin-eosin (H&E) and immunofluorescence staining.
Click to Show/Hide
|
||||
Response regulation | Ursolic acid inhibited tumour cell proliferation and promoted the apoptosis of a variety of osteosarcoma cells. Mechanistic studies showed that ursolic acid degraded ferritin by activating autophagy and induced intracellular overload of ferrous ions, leading to ferroptosis. Ferritin, which includes ferritin light peptide 1 (FTL1) and ferritin heavy peptide 1 (FTH1). | ||||
Ferritin heavy chain (FTH1)
In total 2 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Bavachin | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | |
HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | ||
Response regulation | Bavachin could induce Osteosarcoma cell ferroptosis. Furthermore, bavachin elevated intracellular ferrous iron levels by increasing TFRC and DMT1 expression and decreasing FTH and FTL expressions. Bavachin also reduced SLC7A11 and GPX4 expression and promoted ROS and MDA accumulation by downregulating p-STAT3 to upregulate P53 expression. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [8] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Osteosarcoma [ICD-11: 2B51] | ||||
Responsed Drug | Ursolic Acid | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell apoptosis | |||||
Cell autophagy | |||||
In Vitro Model | HOS cells | Osteosarcoma | Homo sapiens | CVCL_0312 | |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | ||
In Vivo Model |
NU/NU mice (the Fourth Military Medical University, Shaanxi, China) were injected with 143B cells (100 uL, 5 x 107 cells/mL, i.h.). Seven days after the injection, the mice were divided into 6 different groups (n= 3) and intraperitoneally injected with different drugs twice a week. Then, on day 28, the mice were sacrificed, and the tumours in the different groups were weighed. Body weight and tumour size were measured every 3 days from day 7 to day 28. The tumour tissue was fixed with 4% paraformaldehyde, embedded in paraffin, and cut into 4 um thick sections for haematoxylin-eosin (H&E) and immunofluorescence staining.
Click to Show/Hide
|
||||
Response regulation | Ursolic acid inhibited tumour cell proliferation and promoted the apoptosis of a variety of osteosarcoma cells. Mechanistic studies showed that ursolic acid degraded ferritin by activating autophagy and induced intracellular overload of ferrous ions, leading to ferroptosis. Ferritin, which includes ferritin light peptide 1 (FTL1) and ferritin heavy peptide 1 (FTH1). | ||||
References